/

ASMB

Assembly Biosciences, Inc.After hours

20.34−2.43 −10.67%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 20.34 0.00%

Open

22.62

Prev close

22.77

Day range

20.2822.64

52-week range

20.2839.71

Volume

305.63K1.09×

Mkt cap

414.13M

P/E ttm

19.56

Fwd P/E

-7.90

EPS ttm

1.04

Div yield

0.00%

Earnings

—

From 52w high

−48.78%

Price Chart

Yahoo Finance · delayed

ASMBOct 13, 2026O 22.62H 22.64L 20.28C 20.34−2.43 (−10.67%)Vol 305.63K

SMA 5028.44
SMA 20027.97

1Y change −23.27% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ASMB Assembly Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.30%
1 month: −31.74%
3 months: −23.99%
6 months: −30.91%
Year to date: −40.19%
1 year: −26.46%

Valuation & ownership

Market cap: 414.13M
Enterprise value: 145.60M
P/E (ttm): 19.56
Forward P/E: -7.90
PEG ratio: —
Price / book: 1.32
Price / sales (ttm): 5.53
EV / EBITDA: -16.76
EPS (ttm): 1.04
EPS (forward): -2.57
Beta (5y monthly): 1.16
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 20.36M
Float: 9.17M
Short % of float: 18.45%
Short ratio (days): 7.57
Held by insiders: 27.66%
Held by institutions: 69.57%
Avg volume (3m): 281.27K
50-day average: 28.54
200-day average: 28.04
52-week change: −26.46%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 25.9
vs 50-day SMA: −28.48%
vs 200-day SMA: −27.28%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.70%
Realised vol (20d, ann.): 50.7%
From 52-week high: −48.78%
From 52-week low: +0.30%

ANR

Analyst Consensus

5 analysts

Consensus

—

Mean target

52.00

+155.65% implied

Low 43.00Median 52.00High 62.00

Recommendation trend

Now5 / 0 / 0
1m ago4 / 0 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

DES

About Assembly Biosciences, Inc.

Yahoo Finance profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 73
Headquarters: South San Francisco, CA, United States
Website: assemblybio.com
Officers: Mr. Jason A. Okazaki J.D. CEO, President & Director
Dr. William E. Delaney IV, Ph.D. Chief Scientific Officer

SEAS

Seasonality · ASMB

2010–2026 · monthly returns

Strongest month Oct +6.44%Weakest month Jul −3.89%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-24.2	15.7	-7.0	-2.9	2.6	-0.7	-8.6	33.9	-30.2	-13.4			−40.2%
2025	-11.2	-8.1	-25.8	19.1	24.2	28.1	-1.0	37.8	3.6	21.3	21.7	-10.0	+115.5%
2024	14.6	13.4	4.0	-6.2	21.5	-9.4	6.5	11.3	-6.9	11.0	1.4	-7.4	+60.4%
2023	33.8	-21.8	-38.2	23.8	-7.7	19.8	-3.5	-10.8	-10.1	-1.1	-20.5	17.1	−36.9%
2022	-20.2	-16.7	32.9	-14.6	8.5	9.9	-1.4	-9.7	-12.3	0.0	-20.1	-0.8	−44.2%
2021	-7.8	-9.0	-9.4	-7.0	-7.2	-2.3	-10.6	9.5	-8.4	-9.5	-27.0	1.3	−61.5%
2020	-14.2	3.2	-18.2	18.1	11.3	19.7	-4.8	-1.5	-24.8	-10.3	-60.9	4.9	−70.4%
2019	0.7	-6.1	-7.9	-19.9	-11.0	-3.9	-7.3	-9.5	-13.1	68.0	-1.8	26.1	−9.5%
2018	4.3	20.3	-13.4	-11.5	-2.7	-7.3	12.8	-9.6	-7.2	-38.4	12.7	-12.3	−50.0%
2017	52.8	12.3	22.2	-7.3	7.5	-18.7	8.5	21.0	28.8	-15.5	69.1	-9.3	+272.4%
2016	-31.8	-11.3	10.6	19.5	-4.8	-2.8	0.7	9.3	18.0	95.8	-9.0	-5.4	+61.8%
2015	6.9	60.8	-2.0	0.6	25.1	15.6	-22.1	-8.6	-30.3	0.4	2.4	-23.6	−4.5%
2014	11.0	-67.9	-6.6	-15.7	17.8	4.0	-3.4	14.7	12.8	0.0	0.9	-4.8	−58.8%
2013	18.5	19.5	-2.3	-10.4	-3.7	-7.0	-0.4	5.4	14.7	-1.7	6.3	26.5	+76.9%
2012	11.1	20.0	-6.6	-8.6	11.0	-57.8	-14.3	3.3	-5.3	-12.3	-21.0	-12.9	−73.0%
2011	-7.6	29.1	50.0	44.7	-0.9	-13.2	-18.1	-17.7	-9.2	-11.1	-3.6	3.5	+21.0%
2010													—

INSD

Insider Activity · ASMB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

567.9K shares

Sells, 6 months

29 shares

Net shares

+567.9K

Net change in insider shares

+11.20%

Date	Insider	Transaction	Shares	Value
Jun 16, 2026	Bjorkquist Jeanette MOfficer	Sale at price 23.25 per share.	29	$674
May 25, 2026	Gilead Sciences IncBeneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 26.50 per share.	471.7K	$12.50M
Mar 29, 2026	Bjorkquist Jeanette MOfficer	Sale at price 26.65 - 27.49 per share.	328	$8.76K
Mar 29, 2026	White Nicole SOfficer	Sale at price 26.65 - 27.49 per share.	197	$5.26K
Mar 26, 2026	Okazaki Jason AChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	50.8K	—
Mar 26, 2026	Okazaki Jason AChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	94.3K	—
Mar 26, 2026	Delaney William E IvOfficer	Stock Award(Grant) at price 0.00 per share.	14K	—
Mar 26, 2026	Delaney William E IvOfficer	Stock Award(Grant) at price 0.00 per share.	26K	—
Mar 26, 2026	Bjorkquist Jeanette MOfficer	Stock Award(Grant) at price 0.00 per share.	3.5K	—
Mar 26, 2026	Bjorkquist Jeanette MOfficer	Stock Award(Grant) at price 0.00 per share.	6.5K	—
Mar 26, 2026	White Nicole SOfficer	Stock Award(Grant) at price 0.00 per share.	14K	—
Mar 26, 2026	White Nicole SOfficer	Stock Award(Grant) at price 0.00 per share.	26K	—
Mar 26, 2026	Gaggar AnujOfficer	Stock Award(Grant) at price 0.00 per share.	14K	—
Mar 26, 2026	Gaggar AnujOfficer	Stock Award(Grant) at price 0.00 per share.	26K	—
Aug 7, 2025	Gilead Sciences IncBeneficial Owner of more than 10% of a Class of Security	Purchase at price 23.97 per share.	2.30M	$55.03M
Jun 15, 2025	Bjorkquist Jeanette MOfficer	Stock Award(Grant) at price 0.00 per share.	300	—
Mar 30, 2025	Okazaki Jason AChief Executive Officer	Sale at price 9.85 per share.	355	$3.50K
Mar 30, 2025	Bjorkquist Jeanette MOfficer	Sale at price 9.85 per share.	180	$1.77K
Mar 30, 2025	White Nicole SOfficer	Sale at price 9.85 per share.	197	$1.94K
Mar 27, 2025	Bjorkquist Jeanette MOfficer	Stock Award(Grant) at price 0.00 per share.	1.7K	—

13F

Investors Holding ASMB

latest 13F filings of 29 followed managers

Investors holding ASMB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.1M	0.00%	39.44K	+152%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ASMB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ASMB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Assembly Biosciences, Inc.

Seasonality · ASMB

Insider Activity · ASMB

Congress Trades · ASMB

Investors Holding ASMB

Investors Holding ASMB

Congress Trades · ASMB

Insider Activity · ASMB

Seasonality · ASMB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Assembly Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News